According to Sarepta Therapeutics 's latest financial reports and stock price the company's current Operating Margin is -88.19%. At the end of 2022 the company had an Operating Margin of -68.24%.
Year | Operating Margin | Change |
---|---|---|
2022 | -68.24% | 34.77% |
2021 | -50.64% | -44.54% |
2020 | -91.30% | -49.11% |
2019 | -179.40% | 57.16% |
2018 | -114.15% | 23.21% |
2017 | -92.64% | -98.12% |
2016 | -4,920.31% | -72% |
2015 | -17,572.55% | 1181.54% |
2014 | -1,371.21% | 115.95% |
2013 | -634.95% | 697.97% |
2012 | -79.57% | 4.07% |
2011 | -76.46% | 7.45% |
2010 | -71.16% | -19.31% |
2009 | -88.18% | 6.87% |
2008 | -82.52% | -72.62% |
2007 | -301.38% | -98.95% |
2006 | -28,608.52% | 7713.06% |
2005 | -366.16% | -93.71% |
2004 | -5,817.95% | 198.97% |
2003 | -1,945.99% | -35.74% |
2002 | -3,028.39% | 38.83% |
2001 | -2,181.36% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | 26.84% | -130.43% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | -84.20% | -4.52% | ๐บ๐ธ USA |
Novavax NVAX | -149.57% | 69.60% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -108.63% | 23.18% | ๐บ๐ธ USA |
Insmed INSM | -195.69% | 121.90% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | -77.02% | -12.67% | ๐บ๐ธ USA |
Avidity Biosciences RNA | -1,886.32% | 2,038.93% | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.